Dr. Katherine Rotker on destigmatizing sexual health

Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

“The medication is given once a week for 6 weeks. It is an outpatient procedure with general anesthesia. And it is typically covered by insurance,” said Joseph Brito, MD.

Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.